New leg artery scaffold could help thousands with blocked vessels
NCT ID NCT04584632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new device called the efemoral vascular scaffold system (EVSS) in 100 people with blocked leg arteries that cause pain or trouble walking. The scaffold is placed inside the artery to hold it open and improve blood flow. Researchers will check if the device is safe and works well over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2020
- Expected to finish
-
Mar 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Symptomatic peripheral vascular occlusive disease (Rutherford-Becker Clinical Category 2-4) * Patient with life expectancy \>36 months * Females of childbearing potential must have negative pregnancy test * Patient is able to provide informed consent * Patient agrees to undergo all protocol-required follow-up examinations and requirements at the investigational site. * Patient must be able to take antiplatelet and/or anticoagulant agents as prescribed * Single de novo native disease segment of the superficial femoral artery (SFA) or P1 popliteal segment * Reference vessel diameter ≥5.5 mm and ≤6.5 mm * Target lesion length ≤90 mm * Target lesion with ≥50% DS * Inflow artery and popliteal artery free from flow-limiting lesion (DS \<50%) Exclusion Criteria: * Hemoglobin \<9.0 g/dL * WBC \<3,000 cells/mm3 * Platelet count \<80,000 cells/mm3 or \>700,000 cells/mm3 * Acute or chronic renal dysfunction with creatinine \>2.5 mg/dl (176 µmol/L) * Severe liver impairment as defined by total bilirubin ≥3 mg/dl or two times increase over the normal level of SGOT or SGPT * A known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticagrelor or sirolimus, or with contrast sensitivity for which the patient cannot be adequately pre-medicated * Patient requires a planned procedure that would necessitate discontinuation of antiplatelet therapy * Patient is unable to walk * Patient has undergone a percutaneous vascular intervention \<30 days prior to the planned index procedure * Patient is maintained on chronic hemodialysis * Patient has uncontrolled diabetes mellitus (HbA1c ≥7.0%). * Patient has had a myocardial infarction within the previous 30 days of the planned index procedure * Patient has had a stroke within the previous 30 days of the planned index procedure and/or has deficits from a prior stroke that limits the patient's ability to walk * Patient has unstable angina defined as rest angina with ECG changes * Patient has a local groin or acute systemic infection that has not been treated successfully or is currently under treatment * Patient has acute thrombophlebitis, deep vein thrombosis or chronic venous insufficiency in either extremity * Patient has other medical illnesses (e.g., cancer, congestive cardiomyopathy, etc.) that may cause the patient to be non-compliant with protocol requirements, confound the data interpretation or will prevent completion of all required follow up assessments through 36 months * Patient is currently participating in an investigational drug, biologic, or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints * Patient has ischemic or neuropathic ulcers on either foot * Patient has undergone minor or major amputation of either lower extremity * Patient is part of a vulnerable population who, in the judgment of the Investigator, is unable to give informed consent * Target extremity with an angiographically significant (\>50% DS) lesion located distal to the target lesion that requires treatment at the time of the index procedure or by a staged procedure * Acute arterial ischemia of the target extremity * Target extremity has been previously treated with open surgical revascularization (bypass or endarterectomy) * Target vessel has been previously treated with stent, laser, atherectomy, surgical bypass, or endarterectomy * Total occlusion (100% DS) of the ipsilateral inflow artery * Angiographic evidence of thrombus in the target vessel * The target lesion requires treatment with a device other than percutaneous transluminal balloon angioplasty (PTA) \[e.g., orbital atherectomy, directional atherectomy, excimer laser, rotational atherectomy, cryoplasty, etc.\] * Target lesion is within or adjacent to an aneurysm * Patient has angiographic evidence of thromboembolism or atheroembolism from treatment of an ipsilateral iliac lesion or from crossing or pre-dilating the target lesion * Target lesion has moderate-to-severe calcification * Target lesion with \> 30% residual stenosis following pre-dilatation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Femoropopliteal stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
8 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Auckland City Hospital
RECRUITINGAuckland, 1142, New Zealand
-
Canberra Hospital
RECRUITINGCanberra, Australia
-
Christchurch Hospital
RECRUITINGChristchurch, New Zealand
-
Northern Health
RECRUITINGSydney, New South Wales, Australia
-
Prince Of Wales Hospital
RECRUITINGSydney, Australia
-
Royal North Shore
RECRUITINGSydney, Australia
-
The Alfred Hospital
RECRUITINGMelbourne, Australia
-
Waikato Hospital
RECRUITINGHamilton, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatch-Coached walking at home put to the test for leg artery disease
- Could a quieter, automated blood pressure check help more people control hypertension?
- Could pressing instead of plugging let patients walk sooner after leg artery procedures?
- Which artery plug works best? trial pits proglide against femoseal
- Can artery clearing for blocked legs be done without an overnight stay?
- Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs